XVIVO Perfusion AB Reports Third Quarter 2026 Financial Results

XVIVO Perfusion AB reported net sales of SEK 252.6 million for Q3 2026, a 34% increase year-over-year. The company achieved an EBIT of SEK 28.0 million and an EBITDA of SEK 52.0 million. Notable operational milestones included the CE marking of the XVIVO Heart Assist Transport and positive results from a European heart trial. Management highlighted strong organic growth and a focus on market expansion.